Evidence map›Paper›PMID 36513790›Full record

ArticleScientific reports2022

Interpretable prognostic modeling of endometrial cancer.

Bulat Zagidullin, Annukka Pasanen, Mikko Loukovaara, Ralf Bützow, Jing Tang

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Innovations in biomarker stratification for precision oncology.Clinical and experimental medicine · 2026
    Review
  2. Prognostic Role of L1CAM in Endometrial Cancer.Diagnostics (Basel, Switzerland) · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bulat ZagidullinResearch Program in Systems Oncology, Faculty of Medicine, University of Helsinki, 00290, Helsinki, Finland. bulat.zagidullin@helsinki.fi.
Annukka PasanenDepartment of Pathology, University of Helsinki and Helsinki University Hospital, 00290, Helsinki, Finland.
Mikko LoukovaaraDepartment of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, 00290, Helsinki, Finland.
Ralf BützowDepartment of Pathology, University of Helsinki and Helsinki University Hospital, 00290, Helsinki, Finland.
Jing TangResearch Program in Systems Oncology, Faculty of Medicine, University of Helsinki, 00290, Helsinki, Finland. jing.tang@helsinki.fi.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial carcinoma (EC) is one of the most common gynecological cancers in the world. In this work we apply Cox proportional hazards (CPH) and optimal survival tree (OST) algorithms to the retrospective prognostic modeling of disease-specific survival in 842 EC patients. We demonstrate that linear CPH models are preferred for the EC risk assessment based on clinical features alone, while interpretable, non-linear OST models are favored when patient profiles can be supplemented with additional biomarker data. We show how visually interpretable tree models can help generate and explore novel research hypotheses by studying the OST decision path structure, in which L1 cell adhesion molecule expression and estrogen receptor status are correctly indicated as important risk factors in the p53 abnormal EC subgroup. To aid further clinical adoption of advanced machine learning techniques, we stress the importance of quantifying model discrimination and calibration performance in the development of explainable clinical prediction models.

Indexed as

Endometrial NeoplasmsNeural Cell Adhesion Molecule L1Biomarkers, TumorFemaleHumansPrognosisRetrospective StudiesBiomarkers, TumorNeural Cell Adhesion Molecule L1

Identifiers

PMID36513790
PMCPMC9747711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.